Detalles de la búsqueda
1.
Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
Oncologist
; 24(4): 463-474, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30355775
2.
Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study.
Oncologist
; 23(1): 16-24, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29038234
3.
LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.
Endocr Pract
; 24(3): 243-255, 2018 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-29547049
4.
BIOCHEMICAL RESPONSES IN SYMPTOMATIC AND ASYMPTOMATIC PATIENTS WITH NEUROENDOCRINE TUMORS: POOLED ANALYSIS OF 2 PHASE 3 TRIALS.
Endocr Pract
; 2018 Aug 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30084687
5.
EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.
Endocr Pract
; 22(9): 1068-80, 2016 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-27214300
6.
A Patient-Reported Outcomes Analysis Of Lanreotide In The Treatment Of NETs Patients With Carcinoid Syndrome: Evidence From The ELECT Trial.
Patient Relat Outcome Meas
; 10: 335-343, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31754316
7.
A 6-Month Trial of the Efficacy and Safety of Triptorelin Pamoate (11.25 mg) Every 3 Months in Children with Precocious Puberty: A Retrospective Comparison with Triptorelin Acetate.
Horm Res Paediatr
; 86(3): 188-195, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27603324
Resultados
1 -
7
de 7
1
Próxima >
>>